Assessing cardiovascular status using biomarkers and anthropometry among patients with Type-2 Diabetes in a resource limited setting
Background: Diabetes places extra-burden on those affected with the condition particularly in resource constraint settings. Inaccessibility to affordable diagnostic procedures poses a major challenge to the assessment of cardiovascular status in patients with type-2 diabetes in resource limited settings. The study was aimed at evaluating some easily accessible biochemical markers and anthropometric indices implicated in cardiovascular disease amongst T2DM patients.
Methods: One hundred and sixty (160) type-2 diabetic patients grouped into type-2 diabetes only as group 1, type-2 diabetic patients diagnosed with hypertension as group 2, and eighty (80) age and sex-matched controls as group 3, were enrolled in a cross-sectional pattern. Biochemical parameters were assayed using standard laboratory methods. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 20.0 with statistical significance considered at p≤0.05.
Results: The values obtained for diabetic groups were: Glycated Hemoglobin (HbA1c) 9.07±1.99, 10.15±4.98, Total Homocysteine (tHcy) 14.85±52.10, 28.35±100.35, high sensitivity C-reactive protein (hs-CRP) 6.72±6.78,
10.00±11.15, Waist Circumference, 92.58±1.55, 93.65±18.91, Hip Circumference, 96.87±9.01, 98.96±20.33, Systolic Blood Pressure, 113.50±12.94, 135.50±22.72, Diastolic Blood Pressure, 70.75±8.57, 75.38±12.62, Body Mass Index, 25.40±4.70, 26.93±6.50 (among patients) and HbA1c 5.81±0.86, tHcy 0.75±1.44, hs-CRP 5.30±6.19, Waist Circumference 83.15±10.69, Hip Circumference 93.50±22.05, Systolic Blood Pressure, 113.50±10.20, Diastolic Blood Pressure, 77.00±7.19, Body Mass Index, 24.84±4.93 (among controls).
Conclusion: The assessment of some cardio metabolic markers and anthropometric indices may provide easy and accessible tools for prediction and assessment of cardiovascular disease in patients with T2DM especially in resource poor settings.
Annals of Medical Laboratory Science (2021) 1(1), 36 - 48
Chilton R., Singh R. and Ryder R.E. (2017)
Cardiovascular disease and type 2 diabetes:
has the dawn of a new era arrived? Diabetes
Care 40(7), 813-820.
Avramoglu R.K., Basciano H. and Adeli K. (2006) Lipid and lipoprotein dysregulation in insulin resistant states. Clinica chimica acta 368 (1-2), 1-19.
Bansal S., Kapoor S., Singh G. and Yadav S. (2016) Serum Homocysteine Levels in Type 2 Diabetes Mellitus Patients. International Jr of Contemporary Medical Research 3(11), 3393-3396.
Cheung B.M. and Li C. (2012) Diabetes and hypertension: is there a common metabolic pathway? Current atherosclerosis reports 14(2), 160-166.
Chiha M., Njeim M. and Chedrawy E.G. (2012) Diabetes and coronary heart disease: a risk factor for the global epidemic. International journal of hypertension 2012.
DeFronzo R.A. (2009) From the triumvirate to the "ominous octet”: a new paradigm for the treatment of type 2 diabetes mellitus. Clinical Diabetology 10(3), 101-128.
Dongway A.C., Faggad A.S., Zaki H.Y. and Abdalla B.E. (2015) C-reactive protein is associated with low-density lipoprotein cholesterol and obesity in type 2 diabetic Sudanese. Diabetes, metabolic syndrome and obesity: targets and therapy 8427.
Drzewoski J., Czupryniak L., Chwatko G. and Bald E. (1999) Total plasma homocysteine and insulin levels in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care 22(12), 2097.
Eckel R.H., Grundy S.M. and Zimmet P.Z. (2005) The metabolic syndrome. The lancet 365 (9468), 1415-1428.
Eddy D., Schlessinger L., Kahn R., Peskin B. and Schiebinger R. (2009) Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 32(2), 361-366.
Eeg‐Olofsson K., Cederholm J., Nilsson P.,
Zethelius B., Svensson A.M.,
Gudbjörnsdóttir S. and Eliasson B. (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Journal of internal medicine 268(5), 471-482.
El-Maghraby A., Aissa E. and Ibrahim L. (2016) Estimation of homocysteine levels in Type 2 non-hypertensive and hypertensive Diabetic patients. Zagazig University Medical Journal 22(3), 1-8.
Elley C., Kenealy T., Robinson E. and Drury P. (2008) Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabetic Medicine 25(11), 1295-1301.
Gerstein H., Miller M. and Byington R. (2010) Action to control cardiovascular risk in Diabetes study group. Effects of intensive glucose lowering in Type 2 Diabetes.
Gerstein H., Pogue J., Mann J., Lonn E., Dagenais
G., McQueen M. and Yusuf S. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48(9), 1749-1755.
Gillies C.L., Abrams K.R., Lambert P.C., Cooper
N.J., Sutton A.J., Hsu R.T. and Khunti K. (2007) Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Bmj 334(7588), 299.
Giorda C.B., Avogaro A., Maggini M., Lombardo F., Mannucci E., Turco S., Alegiani S.S., Raschetti R., Velussi M. and Ferrannini E. (2007) Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 38(4), 1154-1160.
Gregg E.W., Li Y., Wang J., Rios Burrows N., Ali M.K., Rolka D., Williams D.E. and Geiss L. (2014) Changes in diabetes-related complications in the United States, 1990–2010. New England Journal of Medicine 370(16), 1514-1523.
Hayward R.A., Reaven P.D., Wiitala W.L., Bahn G.D., Reda D.J., Ge L., McCarren M., Duckworth W.C. and Emanuele N.V. (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 372(23), 2197-2206.
Holman R.R., Paul S.K., Bethel M.A., Matthews D.R. and Neil H.A.W. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 359 (15), 1577-1589.
Hopkins P.N. (2013) Molecular biology of atherosclerosis. Physiological reviews 93(3), 1317-1542.
Kenny H.C. and Abel E.D. (2019) Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circulation research 124(1), 121-141.
Khaw K.-T., Wareham N., Bingham S., Luben R., Welch A. and Day N. (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Annals of internal medicine 141(6), 413-420.
Kiran D., Reddy M. and Prakash D. (2017) Evaluation of high sensitive C-reactive protein in development of CVD and stroke among T2 diabetes mellitus. J Forensic Genet Med. 1 (1): 11-16
Lima L.M., Carvalho M.d.G., Soares A.L., Sabino A.d.P., Fernandes A.P., Novelli B.A. and Sousa M.O. (2007) High-sensitivity C-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure. Arquivos brasileiros de endocrinologia & metabologia 51(6), 956-960.
Lopez-Candales A., Burgos P.M.H., Hernandez Suarez D.F. and Harris D. (2017) Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome. Journal of nature and science 3(4).
Lorenzo C., Hartnett S., Hanley A.J., Rewers M.J., Wagenknecht L.E., Karter A.J. and Haffner S.M. (2013) Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. The Journal of Clinical Endocrinology & Metabolism 98(4), 1622-1630.
Low Wang C.C., Hess C.N., Hiatt W.R. and Goldfine A.B. (2016) Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus–
mechanisms, management, and clinical considerations. Circulation 133(24), 2459-2502.
Malaguarnera G., Gagliano C., Giordano M., Salomone S., Vacante M., Bucolo C., Caraci F., Reibaldi M., Drago F. and Avitabile T. (2014) Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy. BioMed research international 2014.
Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., Nissen S.E., Pocock S., Poulter N.R. and Ravn L.S. (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 375(4), 311-322.
Martín-Timón I., Sevillano-Collantes C., Segura-Galindo A. and del Cañizo-Gómez F.J. (2014) Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World journal of diabetes 5 (4), 444.
Patel A., MacMahon S., Chalmers J., Neal B., Cooper M., Glasziou and P. et al. (2008) ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 358(24), 2560-2572.
Petrie J.R., Guzik T.J. and Touyz R.M. (2018) Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian Journal of Cardiology 34 (5), 575-584.
Rahman S., Ismail A.A.-S. and Rahman A.R.A.(2009) Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope? International journal of diabetes in developing countries 29(3), 110.
Rahman S., Majumder M.A.A., Kabir R., Haque M., Gupta S., Arafat S.M.Y. and Dalvi P. (2017) Cardiovascular Disease and Diabetes: Two Sides of the Same Coin. Recent Trends in Cardiovascular Risks71.
Rahman S., Majumder M.A.A. and Rahman A.R.A. (2011) Treatment of diabetic vasculopathy: An overview. Research and Reports in Endocrine Disorders 121-36.
Rosano G.M., Vitale C. and Seferovic P. (2017) Heart failure in patients with diabetes mellitus. Cardiac failure review 3(1), 52.
Schillinger M., Exner M., Amighi J., Mlekusch W., Sabeti S., Rumpold H., Wagner O. and Minar E. (2003) Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 108(19), 2323-2328.
Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R. and Golden S.H. (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of internal medicine 141(6), 421-431.
Smulders Y.M., Rakic M., Slaats E.H., Treskes M., Sijbrands E., Odekerken D., Stehouwer C. and Silberbusch J. (1999) Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 22(1), 125-132.
Tabas I., García-Cardeña G. and Owens G.K. (2015) Recent insights into the cellular biology of atherosclerosis. Journal of Cell Biology 209(1), 13-22.
Tarkun I., Arslan B., Cantürk Z., Tarkun P., Kozdağ G. and Topsever P. (2003) Homocysteine concentrations in type 2 diabetes mellitus patients without cardiovascular disease: relationship to metabolic parameters and diabetic complications. Turkish Journal of Endocrinology and Metabolism 111-17.
WHO. Diabetes (2017) Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html [Accessed: 11-03-2017]
Wilkinson M.J., Zadourian A. and Taub P.R. (2019) Heart failure and diabetes mellitus: defining the problem and exploring the interrelationship. The American journal of cardiology 124S3-S11.
Copyright (c) 2021 Annals of Medical Laboratory Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
As AMLS is an international Open Access magazine, all the articles published under this journal will be accessible to all internet users throughout the world without any barrier of access under the terms of the Creative Commons Attribution License. The copyright of a submitted article is only transferred to the publishers if and when the article is accepted for publication.